Edwards Lifesciences (NYSE:EW) had its target price boosted by Credit Suisse Group from $221.00 to $226.00 in a research note issued to investors on Wednesday morning, The Fly reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A number of other research firms also recently weighed in on EW. Canaccord Genuity downgraded shares of Thomson Reuters from a hold rating to a sell rating in a research report on Wednesday. Morgan Stanley reduced their target price on shares of Neon Therapeutics from $19.00 to $13.00 and set an overweight rating for the company in a research report on Tuesday, July 16th. Raymond James reissued an outperform rating and set a C$44.00 target price on shares of Teck Resources in a research report on Wednesday, April 24th. Deutsche Bank increased their target price on shares of Texas Instruments from $100.00 to $110.00 and gave the company a hold rating in a research report on Wednesday, April 24th. Finally, BTIG Research assumed coverage on shares of in a research report on Wednesday, April 24th. They set a buy rating and a $5.00 target price for the company. Two analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $203.21.

Edwards Lifesciences stock opened at $212.85 on Wednesday. Edwards Lifesciences has a twelve month low of $134.53 and a twelve month high of $219.71. The company’s 50 day moving average is $190.15. The company has a market cap of $44.38 billion, a P/E ratio of 45.29, a P/E/G ratio of 2.68 and a beta of 0.85. The company has a quick ratio of 2.69, a current ratio of 3.38 and a debt-to-equity ratio of 0.18.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.33 by $0.05. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the firm earned $1.24 EPS. The company’s revenue was up 15.2% compared to the same quarter last year. As a group, research analysts expect that Edwards Lifesciences will post 5.34 earnings per share for the current fiscal year.

In related news, VP Larry L. Wood sold 6,716 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $176.34, for a total value of $1,184,299.44. Following the completion of the transaction, the vice president now directly owns 122,495 shares of the company’s stock, valued at approximately $21,600,768.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 3,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $169.60, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now directly owns 20,674 shares of the company’s stock, valued at $3,506,310.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,491 shares of company stock valued at $33,096,783. 1.63% of the stock is owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its position in Edwards Lifesciences by 3.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 601,150 shares of the medical research company’s stock valued at $92,071,000 after purchasing an additional 22,354 shares during the period. Geode Capital Management LLC boosted its position in Edwards Lifesciences by 7.4% during the 4th quarter. Geode Capital Management LLC now owns 2,942,494 shares of the medical research company’s stock valued at $449,976,000 after purchasing an additional 202,248 shares during the period. Squarepoint Ops LLC boosted its position in Edwards Lifesciences by 403.4% during the 4th quarter. Squarepoint Ops LLC now owns 11,074 shares of the medical research company’s stock valued at $1,696,000 after purchasing an additional 8,874 shares during the period. Municipal Employees Retirement System of Michigan acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $856,000. Finally, Voloridge Investment Management LLC acquired a new position in Edwards Lifesciences during the 4th quarter valued at approximately $438,000. 81.95% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Read More: Momentum Indicators

The Fly

Analyst Recommendations for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.